Hugel Surpasses 200 Billion KRW in First-Half Sales, Achieving Record High

Hugel Co., Ltd. reported consolidated financial results for the second quarter of this year, posting sales of 110.3 billion KRW, operating profit of 56.7 billion KRW, and net profit of 38.2 billion KRW. These figures represent year-on-year increases of 15.5%, 33.6%, and 3.3%, respectively, marking the highest quarterly performance in the company's history.

For the first half of this year, Hugel's sales exceeded 200 billion KRW, and operating profit surpassed 95 billion KRW.

In the second quarter, overseas sales of the company's main products?botulinum toxin and HA fillers?grew by 21% year-on-year to 69.8 billion KRW, accounting for 63% of total sales and significantly driving quarterly performance. Notably, Hugel is the first and only domestic company to have obtained approval in all three major global toxin markets: the United States, China, and Europe. Buoyed by robust sales in these regions, exports accounted for 73% of combined toxin and filler sales in the second quarter.

By product, sales of the botulinum toxin 'Botulax' (export name: Letibot) reached 61.2 billion KRW, up 20% from a year earlier, with cumulative sales for the first half exceeding 100 billion KRW. The company explained that following the product's launch in the United States in March of this year, additional shipments to the U.S. took place in June, and stable growth was also seen in Asia-Pacific countries such as China, Taiwan, and Australia.

Sales of HA fillers ('The Chaeum' and 'Byryzn Skin Booster HA') reached 34.1 billion KRW, supported by steady growth in the Asia-Pacific and European markets. Sales in the cosmetics segment ('Wellage' and 'Byryzn BR') surged by approximately 105% year-on-year to 13.6 billion KRW.

A Hugel representative emphasized, "In addition to our main product lines of botulinum toxin and HA fillers, our new growth driver?the cosmetics segment?also performed strongly, allowing us to achieve record-high quarterly sales and operating profit, as well as surpassing 200 billion KRW in sales for the first half of the year."

The representative added, "In the second half of the year, we plan to further increase our penetration in the U.S. market, where we have begun full-scale exports, leveraging the excellence and competitiveness of Hugel's toxin products. We will also continue to focus on strengthening our leading position in China and expanding our market share in emerging markets such as the Middle East."

This content was produced with the assistance of AI translation services.